Latest News 7 October 2008 - EUROBIO 2008 Paris: Meet and partner with Rhenovia in Paris 7-9 October
CONFERENCES
The
combination of this year’s French Presidency of the European Union and
EuroBiO 2008 will empower those who understand the challenges to design
the changes needed for the 21st century. Come and meet the key “doers” from large Life Sciences corporations,
biotechnology companies, brilliant young start-ups, leading
bioclusters, academic research institutions, CROs and service providers
who are shaping, and driving, bioindustry in Europe.
EuroBiOpartnering 2008 focuses the spotlight on innovation and best
practices and the way in which these drive successful private-public
partnerships, technology transfer and the successful meshing of leading
European bioclusters EuroBiOpartnering 2008 focuses the spotlight on innovation and best
practices and the way in which these drive successful private-public
partnerships, technology transfer and the successful meshing of leading
European bioclusters 19 September 2008 - Partnership between Altran Est (The european leader in innovation consulting) and Rhenovia Pharma
Altran, European leader in innovation consulting
Created in 1982, Altran is today the European leader in innovation consulting.
Our originality lies in the ability of our consultants to manage our customer's projects that deliver tomorrow’s solutions today.
Built on an original model, then decentralised to give free rein to initiative, Altran assists its clients at every stage of the innovation cycle in three complementary fields:
 technology and innovation consulting (accounting for nearly half the turnover),
organisation and information systems consulting (a third of the turnover),
strategy and management consulting. In 2007, the Group’s turnover reached 1 591,4 million euros, with over 17,000 employees in the 20 top countries. AltranOct08_FR.pdf 25 July 2008 - Dr. Serge Braun : New scientific advisory board member of Rhenovia
Dr. Serge Braun , 48 years old is Scientific Director of AFM, the French Neuromuscular diseases Association. He has 10 years experience in the University and 10 years in th ebiotechnology sector. He obtained his degree in Phgarmacy and a PhD in Pharmacology from the University Louis Pasteur of Strasbourg, France. he joined from 1990-1992 as postdoctoral fellow the neuromuscular Center School of Medicine of the University of Southern California in Los Angeles,USA.
From 1992 to 1995, he returned as Research assistant to the School of Pharmacy of Strasbourg working on the patognesis and treatment of different genetic and acquired neuromuscular diseases. In 1995 he joined Transgene ( Strasbourg) where he became Scientific Director and developped his career in the field of gene therapy of genesic diseases and of immunotherapy cancer. He was co-founder of Neurofit a contract research organization specialized in preclinical testing of both the central and the peripheral nervous system. He was vic president of Alsace Biovalley, the tri-national initiative, non profit organization, for the development of a major biotech cluster in Europe.He is also scientific expert of different state organisms non profit organization, VC's and reviewer of major journals
22 July 2008 - Eurostars label for Rhenovia Pharma
EUREKA's Eurostars Programme is the first European
funding and support programme to be specifically dedicated to SMEs.
Eurostars will stimulate them to lead international collaborative
research and innovation projects by easing access to support and
funding. Rhenovia Pharma submitted Project "Altheras " was recognised ( June 6, 2008) as one of the best Project and became a laureate of EUREKA's Eurostars in july10 July 2008 - Rhenovia and the Blue Brain Project Meeting: in Geneva
The Blue Brain Project is hosting a satellite meeting just before the
FENS 2008 meeting at the PalEXPO center in Geneva, Switzerland, from
July 10-11, 2008.
The Blue Brain Project: Reverse-Engineering Biological Intelligence
Biological intelligence exists in the organizing principles of
biological networks, from gene regulatory networks, to signaling and
metabolic networks, to the complex neural circuitry of the brain.
Reverse-engineering in systems biology has traditionally focused on
the reconstruction of these networks within individual cells based on
measured data of the genome, transcriptome, proteome and metabolome.
In computational neuroscience, reverse engineering has focused on
networks of cells in the brain. However, reverse-engineering efforts
must seek and characterize the organizing principles across all types
of biological networks. In order to achieve this level of reverse
engineering, industrial scale efforts are required to systematically
gather biological data and assemble computational models to explore
the solutions biology has engineered to build living cells and produce
intelligence.
The Blue Brain Project invites you to join an open discussion on
future directions in reverse engineering large-scale biological
systems, with presentations from world experts in systems biology,
simulation and computing. This meeting will also provide a unique
opportunity to hear from the Blue Brain team itself, with
presentations on the tools and workflow of reconstructing and
simulating the neocortical column.
Day 1: Reverse Engineering Biological Intelligence
A group of experts in systems biology and neuroscience present their
visions for the future of large-scale systems biology efforts.
Confirmed speakers:
Henry Markram - Blue Brain Project and Brain Mind Institute, EPFL
Michel Baudry - Rhenovia and University of Southern California
Mark Ellisman - UCSD
Mark Potse - University of Montreal
Thomas Bartol - The Salk Institute
Gustavo Stolovitzky - IBM Research
7 July 2008 - Rhenovia invited by the French government at the European Innovation ConférenceRhenovia (Michel Faupel) is invited by the
Ministère de l'enseignement supérieur et de la recherche
8 April 2008 - Pr. Henry Markram; New scientific advisory board member of Rhenovia Professor Henry Markram, Project Director of the Blue Brain Project, Director of the Center for Neuroscience & Technology
becomes member of the Rhenovia Advisory board 28 February 2008 - Highly Cited Researchers: Pr. Michel Baudry co-founder of Rhenovia
Michel Baudry, our VP Research & Development is among the 100 most cited neuroscientists.
The Institute for Scientific Information's Web of Knowledge compiles a Highly Cited list composed of the most highly cited individuals within each of 21 broad subject categories.
Neuroscientist Larry W. Swanson was among the 100 most-cited scientists in the world for all fields in a decade.
And...
21 February 2008 - Partnership with the Association Alsace Alzheimer 68
Rhenovia Pharma, jeune entreprise de recherche
biopharmaceutique dont le siège est à Mulhouse, a formalisé jeudi
dernier un partenariat avec l'association Alsace Alzheimer 68, qu'elle
informera de ses progrès scientifiques.
1 November 2007 - Michel Faupel is nominated as expert at the European Community
Michel Faupel, our VP new technologies, is nominated as expert (life sciences and health) to establish the EUROPEAN TECHNOLOGY PLATFORM (European Union / Brussels) 15 October 2007 - Novel Drug Discovery Strategy for Alzheimer's and Other Brain DiseasesThe unmet medical needs, especially for Alzheimer’s disease, are mostly due to the fact that all brain pathologies are extremely complex, multifactorial and dynamic.
Read more in the following document: eurobiolille Rhenovia[1].doc |
)
)
)
)
)
)
)
)
